ClinConnect ClinConnect Logo
Search / Trial NCT02300766

Cerebellar Mutism Syndrome Study

Launched by RIGSHOSPITALET, DENMARK · Nov 24, 2014

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Cerebellar Mutism Syndrome Posterior Fossa Tumor Pediatric Cancer Neurosurgical Techniques

ClinConnect Summary

The Cerebellar Mutism Syndrome Study is looking into why some children develop a condition called Cerebellar Mutism Syndrome (CMS) after having surgery for brain tumors in the back part of the brain, known as the posterior fossa. This condition can affect their ability to speak and communicate. The study aims to understand how often this happens, what the typical recovery looks like, and the best ways to treat it.

To participate in the study, children must be under 18 years old and have a tumor located in the cerebellum, the fourth ventricle, or the brainstem. The study is open to all genders, and parents or guardians will need to give their consent for their child to join. If eligible, participants can expect to be part of a research team that will closely monitor their condition and treatment progress. The study is currently recruiting participants, and there are no specific exclusion criteria, making it accessible for many families dealing with this challenging situation.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \< 18 years at the date of first imaging showing this tumour
  • Tumour in the cerebellum/4th ventricle/brainstem with intention to treat with surgical resection or open biopsy. Second and further surgeries are also included.
  • Informed consent from custodial parent(s)
  • Exclusion Criteria:
  • None

About Rigshospitalet, Denmark

Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.

Locations

Helsinki, , Finland

Copenhagen, , Denmark

Uppsala, , Sweden

Aarhus, , Denmark

Odense, , Denmark

Vienna, , Austria

Gothenburg, , Sweden

Utrecht, , Netherlands

Oulu, , Finland

Kuopio, , Finland

Tampere, , Finland

Stockholm, , Sweden

Bergen, , Norway

Aalborg, , Denmark

Linköping, , Sweden

Leuven, , Belgium

Oslo, , Norway

Turku, , Finland

Trondheim, , Norway

Groningen, , Netherlands

Tromsø, , Norway

Rome, , Italy

Kaunas, , Lithuania

Umeå, , Sweden

Budapest, , Hungary

Nijmegen, Gelderland, Netherlands

Skåne, , Sweden

Liverpool, , United Kingdom

Praha, , Czechia

Leipzig, , Germany

Patients applied

0 patients applied

Trial Officials

Kjeld Schmiegelow, MD, Dr. med

Study Chair

Rigshospitalet, Denmark

Marianne Juhler, MD, Dr. med

Principal Investigator

Rigshospitalet, Denmark

Karsten Nysom, MD

Study Chair

Rigshospitalet, Denmark

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials